REGN-COV2
Experimental drug (antibody cocktail against SARS-CoV-2) developed by Regeneron
REGN-COV2 ▸ Facts ▸ Comments ▸ News ▸ Videos
REGN-COV2 is an experimental drug developed by the American biotechnology company Regeneron Pharmaceuticals. It is an artificial "antibody cocktail" designed to produce resistance to the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic. It consists of a mixture of two monoclonal antibodies, REGN10933 and REGN10987. The combination of several antibodies is intended to prevent mutational escape.
| 0 shares | ShareTweetSavePostSend |
You Might Like
Covid-19: Antibody cocktail used to treat Trump launched in India at Rs 59,750/doseThe price for each patient dose [a combined dose of 1,200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] will be Rs 59,750 inclusive of all taxes. The maximum retail price for the multi dose pack..IndiaTimes - Published |
| Search this site and the web: |
